Drug Profile
Research programme: IKur antagonists - Bristol-Myers Squibb
Alternative Names: IKur antagonistsLatest Information Update: 09 Sep 2014
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Small molecules
- Mechanism of Action Kv1.5 potassium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Atrial fibrillation
Most Recent Events
- 10 Jul 2014 No development reported - Preclinical for Atrial fibrillation in USA (unspecified route) prior to July 2014